← All trials
NCT04026230
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2019
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TampereLead sponsor
- University of TurkuCollaborator
- University of TurkuStudy director
- University of HelsinkiCollaborator
- Kuopio University HospitalCollaborator
- University of TampereOverall official - principal investigator
- University of TampereReponsible party - principal investigator
- Aarhus UniversityCollaborator
- University of HelsinkiStudy director
- University of TartuCollaborator
- Government of FinlandCollaborator
- Fimlab laboratoriesCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.